Monoclonal antibodyPhase 3 trialInvestigational
MM-151
Generic name: mabuparituximab
How it works
MM-151 is an antibody that targets the CD19 receptor on cancer cells, allowing the immune system to attack them.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that MM-151 can improve overall survival in patients with pancreatic cancer, with a median survival of approximately 8.5 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.